Skip to main content
Top
Published in: Nutrition Journal 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

Authors: Tatsuya Ohara, Koutarou Muroyama, Yoshihiro Yamamoto, Shinji Murosaki

Published in: Nutrition Journal | Issue 1/2017

Login to get access

Excerpt

After publication of this article [1] it was noticed there were errors in the paper regarding the dose and grade of glucosyl hesperidin due to miscommunications. …
Literature
1.
go back to reference Ohara T, Muroyama K, Yamamoto Y, Murosaki S. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2016;15:6.CrossRefPubMedPubMedCentral Ohara T, Muroyama K, Yamamoto Y, Murosaki S. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2016;15:6.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial
Authors
Tatsuya Ohara
Koutarou Muroyama
Yoshihiro Yamamoto
Shinji Murosaki
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Nutrition Journal / Issue 1/2017
Electronic ISSN: 1475-2891
DOI
https://doi.org/10.1186/s12937-017-0253-6

Other articles of this Issue 1/2017

Nutrition Journal 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.